Avacta Group plc (AIM: AVCT), a clinical-stage life sciences company focused on targeted oncology therapies, has announced it will present its next-generation dual payload candidate AVA6207 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, from 18 to 20 November 2026. AVA6207 is a peptide-drug conjugate built on Avacta's proprietary pre|CISION® platform, designed to deliver two synergistic cancer-fighting payloads simultaneously to tumour cells. The presentation underscores Avacta's expanding pipeline beyond its lead clinical programme and signals growing scientific validation of the pre|CISION® technology in hard-to-treat cancers.

Key Points

  • Avacta Group plc (AIM: AVCT) is a clinical-stage UK life sciences company developing targeted oncology drugs via its pre|CISION® platform
  • AVA6207, a dual payload peptide-drug conjugate targeting TOP1i-resistant cancers, will be presented in a poster session at the 2026 EORTC-NCI-AACR Symposium
  • The poster presentation is scheduled for Thursday 19 November 2026 (09:00–17:30), Exhibition Hall, Poster Area, Abstract Number 161
  • Investors should watch for scientific reception of AVA6207 data and any subsequent development timeline disclosures from the company

AVA6207 Combines TOP1 Inhibition and ATR Kinase Blockade in a Single pre|CISION® Molecule

AVA6207 is designed to tackle highly resistant cancers by combining two complementary mechanisms within a single molecule. The compound inhibits topoisomerase I (TOP1), inducing severe DNA damage in tumour cells, while simultaneously deploying an ATR kinase inhibitor (ATRi) to block the DNA damage response, preventing cancer cells from repairing the damage caused by the TOP1 inhibitor. The announcement states that this dual payload approach uses Avacta's pre|CISION® PDC technology to deliver both agents directly to the tumour, with the goal of improving outcomes in TOP1 inhibitor-resistant cancers — an area the company describes as a growing unmet need in oncology.

FAP-Cleavage Mechanism Underpins Avacta's Tumour-Targeted Delivery Strategy for AVA6207

The poster's full title indicates that AVA6207 delivers its complementary payloads to the tumour microenvironment following cleavage by Fibroblast Activation Protein (FAP), a tumour-specific protease central to Avacta's pre|CISION® platform. This mechanism is designed to concentrate highly potent payloads within the tumour while sparing healthy tissue, addressing a key limitation of systemic cancer therapies. The announcement notes that pre|CISION® PDCs operate in a small molecule format, distinguishing them from antibody-drug conjugates (ADCs) by offering alternative delivery beyond antibodies and potentially reducing systemic exposure and toxicity.

AVA6207 Presentation Sits Alongside Avacta's Lead FOCUS-01 Phase 1 Trial in AVA6103

AVA6207 is a pipeline candidate presented alongside Avacta's lead clinical programme, AVA6103, which is currently being evaluated in the FOCUS-01 Phase 1 trial across tumour types including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer, and pancreatic cancer. AVA6103 also employs the pre|CISION® controlled release mechanism for direct intratumoral payload delivery. The Barcelona symposium presentation of AVA6207 — authored by Victoria Juskaite, Tom Clough, Ellen Watts, and David Jones among others — represents an early-stage data disclosure; the company has not disclosed clinical trial timelines or financial metrics for AVA6207 in this announcement.